

1. Record Nr.	UNINA9910959758103321
Titolo	Saving lives, buying time : economics of malaria drugs in an age of resistance // Committee on the Economics of Antimalarial Drugs, Board on Global Health ; Kenneth J. Arrow, Claire Panosian, and Hellen Gelband, editors
Pubbl/distr/stampa	Washington, D.C., : National Academies Press, c2004
ISBN	9786610176120 9780309165938 0309165938 9781280176128 1280176121 9780309532334 0309532337
Edizione	[1st ed.]
Descrizione fisica	1 online resource (384 p.)
Altri autori (Persone)	ArrowKenneth Joseph <1921-> PanosianClaire GelbandHellen
Disciplina	616.9/362061
Soggetti	Antimalarials - Economic aspects Pharmaceutical policy Drug resistance in microorganisms Malaria - drug therapy Antimalarials - therapeutic use Drug Costs Drug Resistance
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Bibliographic Level Mode of Issuance: Monograph
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	FrontMatter -- Reviewers -- Preface -- Acknowledgments -- Contents -- Executive Summary -- PART 1 A Response to the Current Crisis -- 1 Malaria Today -- 2 The Cost and Cost-Effectiveness of Antimalarial Drugs -- 3 The Case for a Global Subsidy of Antimalarial Drugs -- 4 An International System for Procuring Antimalarial Drugs -- PART 2 Malaria Basics -- 5 A Brief History of Malaria -- 6 The Parasite, the

Mosquito, and the Disease -- 7 The Human and Economic Burden of Malaria -- 8 Malaria Control -- 9 Antimalarial Drugs and Drug Resistance -- PART 3 Advancing Toward Better Malaria Control -- 10 Research and Development for New Antimalarial Drugs -- 11 Maximizing the Effective Use of Antimalarial Drugs -- Acronyms and Abbreviations -- Glossary -- Index.

---

## Sommario/riassunto

For more than 50 years, low-cost antimalarial drugs silently saved millions of lives and cured billions of debilitating infections. Today, however, these drugs no longer work against the deadliest form of malaria that exists throughout the world. Malaria deaths in sub-Saharan Africa "currently just over one million per year" are rising because of increased resistance to the old, inexpensive drugs. Although effective new drugs called artemisinins are available, they are unaffordable for the majority of the affected population, even at a cost of one dollar per course. *Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance* examines the history of malaria treatments, provides an overview of the current drug crisis, and offers recommendations on maximizing access to and effectiveness of antimalarial drugs. The book finds that most people in endemic countries will not have access to currently effective combination treatments, which should include an artemisinin, without financing from the global community. Without funding for effective treatment, malaria mortality could double over the next 10 to 20 years and transmission will intensify.

---